Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04131738 · ClinicalTrials.gov registry record · Phase 1
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
A Phase 1 study of Graft-Versus-Host Disease and Graft Vs Host Disease, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT04131738 is a Phase 1 study of Graft-Versus-Host Disease and Graft Vs Host Disease that has completed, run by Washington University School of Medicine. The registered enrollment target is 26 participants, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04131738, a Phase 1 study of Graft-Versus-Host Disease and Graft Vs Host Disease, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
In this trial, the investigators will begin to explore the possibility that, as in mice, JAK1/2 inhibition with hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) while retaining engraftment and Graft-versus-Leukemia (GVL). Both preclinical and clinical data suggest that inhibition of IFNy and IL-6, directly and using downstream JAK Inhibitors, may be an effective strategy to decrease toxicities and improve disease control for patients undergoing Allogeneic HSCT. Baricitinib, as a JAK1/2 inhibitor, has shown superiority to other JAK inhibitors in preclinical GVHD models. The purpose of this phase I clinical trial is to determine the safety of baricitinib with HSCT measured by the effect on engraftment and grade III-IV acute graft-versus-host-disease (aGVHD).
Conditions Studied
Interventions
- DRUG Baricitinib
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2022-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04131738
The ClinicalTrials.gov registry entry for NCT04131738 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (68% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Baricitinib is the first listed.
NCT04131738 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04131738 about?
NCT04131738 is a clinical study titled "Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation". In this trial, the investigators will begin to explore the possibility that, as in mice, JAK1/2 inhibition with hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) while retaining engraftment and Graft-versus-Leukemia (GVL). Both preclinical and clinical data sugge...
What is the current status of trial NCT04131738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2020-04-07. Estimated completion is 2022-08-17.
What conditions does trial NCT04131738 study?
This clinical trial studies the following conditions: Graft-Versus-Host Disease, Graft Vs Host Disease.
What interventions are being tested in trial NCT04131738?
The interventions under investigation include: Baricitinib (DRUG).
Who is sponsoring clinical trial NCT04131738?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04131738 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft-Versus-Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 1
-
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
RECRUITING · Phase 1
-
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Optimizing PTCy Dose and Timing
ACTIVE NOT RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.